IIIlaha Isali

Ilaha Isali

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ilaha Isali has a total of 72 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Understanding Risk Factors for Stress Urinary Incontinence in Women: A Narrative Review

    by Haitong Yu, Madelyn Broghammer, Thomas R. Wong, Minneh Song, Ilaha Isali

  • Open Access

    From bench to bedside: A narrative review of regenerative medicine approaches for postprostatectomy incontinence

    by W. Garrett Haffke, Thomas R. Wong, Runzhuo Ma, Laura E. Davis, Ilaha Isali

    Postprostatectomy urinary incontinence (PPUI) is a prevalent complication following radical prostatectomy, with long‑term incontinence affecting up to one‑third of patients. Conventional treatments are limited by inconsistent efficacy, side effects or invasiveness, indicating demand for alternative therapies. This narrative review assessed clinical evidence of regenerative therapies, especially autologous stem cell approaches, for PPUI. We searched multiple databases for studies published between 2010 and 2024; eligible articles were clinical trials using stem cell therapies for PPUI, while non‑PPUI incontinence or non‑clinical outcome studies were excluded. Eight studies enrolling 311 patients were included: six used adipose‑derived stem cells (ADSCs) and two used muscle‑derived cells, administered via periurethral, transurethral or surgical implantation. Overall, 43.7% of patients achieved continence improvement, with efficacy ranging from 0% to 100% across studies; adverse events were mostly mild and self‑limiting. However, heterogeneity in study design, small sample sizes, inconsistent outcomes and short follow‑up restricted generalizability. Regenerative cell therapies, particularly ADSCs, are promising and well‑tolerated for PPUI. ADSCs are superior in easy harvest, scalability and multilineage differentiation. Although early data are encouraging, large‑scale, long‑term studies are required to confirm efficacy, optimize delivery and evaluate long‑term safety and durability.

  • Open Access

    Comparative analysis of male stress urinary incontinence treatments: A review of efficacy, safety, and clinical outcomes

    by Sindhu Kosuru, Cosku Ozcelik, Thomas R. Wong, Isaac Mordukhovich, Narmina Khanmammadova, Ilaha Isali

    Background: Male stress urinary incontinence (MSUI) is a distressing condition that often results from radical prostatectomy, transurethral resection of the prostate, or other pelvic procedures. Despite the limitations of artificial urinary sphincters they have historically been considered the gold standard. Emerging treatments offer varying efficacies and safety levels. This study aimed to evaluate and compare the efficacy, safety, and clinical outcomes of current MSUI treatment modalities, including artificial urinary sphincters, adjustable transobturator male system (ATOMS), Pro Adjustable Continence Therapy, AdVance Non-adjustable Male Sling System, and duloxetine. Materials and methods: PubMed, covering prospective and retrospective analyses of MSUI treatments in postprostatectomy patients, was searched for relevant studies published between 2006 and 2024. Data on treatment efficacy (dry matter rate, improvement rate, and reduction in incontinence severity) and safety outcomes (complication and explanation rates) were extracted. Results: A total of 46 studies comprising 7841 patients were analyzed. Artificial urinary sphincters demonstrated the highest dryness rate (72.03%), whereas ATOMS had the highest improvement rate (85.56%) and the lowest surgical explantation risk (9.45%). Pro Adjustable Continence Therapy and AdVance yielded moderate efficacy, whereas duloxetine had the lowest complication rate (18.79%). Conclusions: Artificial urinary sphincters may be the most effective treatment for dryness, whereas ATOMS could offer high improvement rates with a lower risk of explantation and complications. Duloxetine demonstrated a strong safety profile as a pharmacological option, although the evidence remains limited. Given the heterogeneity of the existing studies, future prospective randomized trials are needed to refine treatment selection and optimize MSUI management.


  • Midurethral Sling Surgery: Impacts on Sexual Function and Approaches to Complications

    by Minneh Song, Thomas Reid Wong, Ilaha Isali

    Stress urinary incontinence (SUI) is highly prevalent among adult women and can significantly impact quality of life (QoL), including sexual function (SF). The midurethral sling (MUS) has become the gold-standard intervention for SUI owing to its high efficacy and minimal invasiveness. However, its impact on SF is less well understood. This review is aimed at examining the impact of MUS techniques on SF in women with SUI and outlines evidence-based interventions for managing MUS complications or failure. The PubMed database was searched to identify original, peer-reviewed articles published from 2014 to 2025 that examined changes in SF and treatment options in patients undergoing MUS surgery for SUI. Ninety-eight studies were included in this review. Our analysis found that most studies reported an improvement or preservation of SF following MUS placement. However, surgical outcomes varied depending on the type of sling, follow-up duration, and individual patient characteristics. A subset of patients may also experience postoperative complications such as mesh exposure and recurrent incontinence, requiring further intervention. Treatment options after MUS failure range from conservative approaches, including pelvic floor muscle training and steroid injections, to more invasive surgical interventions such as sling mobilization or removal, urethral bulking injections, and repeat SUI surgeries. Further long-term studies using validated SF instruments are needed to guide clinical decision-making and optimize outcomes for women undergoing MUS surgery.


  • Rethinking Urethral Diverticulum: A Narrative Review of Clinical Outcomes and Cancer Associations

    by Carolyn Daniels, Thomas R. Wong, Ilaha Isali

    Urethral diverticulum (UD) is a rare condition characterized by a pouch-like protrusion of the urethral mucosa into surrounding tissues. This review is aimed at synthesizing data on factors influencing surgical outcomes, postoperative complications, and the association between UD and malignancy. A comprehensive literature search was conducted for studies published between 2014 and 2024. Inclusion criteria encompassed studies reporting patient outcomes post-UD repair, postoperative complications, or cases of UD-associated malignancy. Data were extracted and analyzed qualitatively owing to the heterogeneity of available studies. Thirty-two studies met the inclusion criteria, totaling 1052 patients with a median age range of 35-62 years; 86% of the patients were female. Transvaginal surgical excision has demonstrated success rates of 83% to 97%. Recurrence rates varied, with primary diverticulectomy showing 2% to 22% and urethroplasty 17%. Larger diverticula (> 3 cm) were linked to increased intraoperative blood loss (mean 450 ml vs 200 ml, p < 0.001). Anatomical complexity, such as circumferential diverticula, was associated with higher postoperative urinary tract infection rates (15% vs 7%, p = 0.02) and reduced surgical success (83% vs 97%, p < 0.05). Postoperative stress urinary incontinence occurred in 4% to 21% of patients. Eighteen cases of UD-associated malignancy were identified, predominantly adenocarcinoma (44%), with a mean age at diagnosis of 51.6 years. Surgical outcomes for UD are influenced by factors such as diverticulum size and anatomical complexity. Postoperative complications are significant considerations. Further research with standardized reporting is essential to enhance understanding and management of UD.


  • The role of angiogenin in bladder cancer: where are we in 2025?

    by Thomas R. Wong, Clara Sun, Braian Ledesma, Ilaha Isali

    Purpose The diagnosis of bladder cancer (BCa), a condition that represents approximately 4% of new cancer cases in the United States, could be greatly improved by the development of non-invasive biomarker-based testing. Current diagnostic methods include cystoscopy and cytology; however, these techniques are overly invasive and may cause patient discomfort. Angiogenin (ANG), a member of the RNase A superfamily, was implicated in tumor growth due to its role in angiogenesis. ANG pathophysiology and potential diagnostic and therapeutic role in BCa are discussed. Methods A narrative review was conducted on the relationship between ANG and BCa. Articles were retrieved from PubMed and Google Scholar between the years of 2000 and 2024. The authors reviewed the included articles and summarized findings. Results In BCa, ANG interacts with matrix metallopeptidase 2 (MMP2) through the ERK1/2 signaling pathway and contributes to extracellular matrix (ECM) degradation. This review, including 9 articles that directly assessed biomarker-based tests with ANG, suggests that ANG may be suitable for developing novel diagnostic urine biomarker tests. The overexpression of ANG in patients with BCa may also suggest the potential for developing therapeutics that target this protein. Some articles indicate that ribonuclease inhibitors could successfully target ANG by limiting nuclear translocation or limiting ANG activation of phosphatidylinositol 3-kinase (PI3K)/protein kinase B (AKT)/mammalian target of rapamycin (mTOR) pathways, thus limiting BCa progression. Conclusions The results of this review warrant further investigation into both the diagnostic and therapeutic potential of ANG in BCa. Future case–control studies and clinical trials are needed.


  • Dexamethasone eluting polydopaminated polycaprolactone‐poly (lactic‐co‐glycolic) acid for treatment of tracheal stenosis

    by Jacob Morand, Phillip McClellan, Ilaha Isali, Yusuf Dikici, Di Fan, Longshun Li, Andrew J. Shoffstall, Ozan Akkus, Mark Weidenbecher

    Tracheal stenosis is commonly caused by injury, resulting in inflammation and fibrosis. Inhibiting inflammation and promoting epithelization can reduce recurrence after initial successful treatment of tracheal stenosis. Steroids play an important role in tracheal stenosis management. This study in vitro evaluated effectiveness of a polydopaminated polycaprolactone stent coated with dexamethasone‐eluting poly(lactic‐co‐glycolic) acid microparticles (μPLGA) for tracheal stenosis management. Polydopamination was characterized by Raman spectroscopy and promoted epithelialization while dexamethasone delivery reduced macrophage activity, assessed by individual cell area measurements and immunofluorescent staining for inducible nitric oxide synthase (iNOS). Dexamethasone release was quantified by high‐performance liquid chromatography over 30 days. Activation‐related increase in cell area and iNOS production by RAW 264.7 were both reduced significantly (p < .05) through dexamethasone release. Epithelial cell spreading was higher on polydopaminated polycaprolactone (PCL) than PCL‐alone (p < .05). Force required for stent migration was measured by pullout tests of PCL‐μPLGA stents from cadaveric rabbit and porcine tracheas (0.425 ± 0.068 N and 1.082 ± 0.064 N, respectively) were above forces estimated to occur during forced respiration. Biomechanical support provided by stents to prevent airway collapse was assessed by comparing compressive circumferential stiffness, and stiffness of the stent was about 1/10th of the rabbit trachea (0.156 ± 0.023 N/mm vs. 1.420 ± 0.194 N/mm, respectively). A dexamethasone‐loaded PCL‐μPLGA stent platform can deliver dexamethasone and exhibits sufficient mechanical properties to anchor within the trachea and polydopamination of PCL is conducive to epithelial layer formation. Therefore, a polydopaminated PCL‐μPLGA stent is a promising candidate for in vivo evaluation for treatment of tracheal restenosis.


  • In Vivo Delivery of M0, M1, and M2 Macrophage Subtypes via Genipin-Cross-Linked Collagen Biotextile

    by Ilaha Isali, Phillip McClellan, Thomas R. Wong, Snigdha Cingireddi, Mukesh Jain, James M. Anderson, Adonis Hijaz, Ozan Akkus

    Developing strategies to regulate the immune response poses significant challenges with respect to the clinical translation of tissue-engineered scaffolds. Prominent advancements have been made relating to macrophage-based therapies and biomaterials. Macrophages exhibit the potential to influence healing trajectory, and predominance of particular subtypes during early onset of healing influences repair outcomes. This study evaluated short- and long-term healing response and postoperative mechanical properties of genipin-cross-linked, electrochemically aligned collagen biotextiles with comparative administration of M0, M1, and M2 subtypes. Irrespective of macrophage subtype seeded, all the groups demonstrated existence of M2 macrophages at both time points as typified by arginase and Ym-1 expressions, and distinct absence of M1 macrophages, as indicated by lack of inducible nitric oxide synthase (iNOS) and interleukin-1β expression in all the groups for both time points. M2 macrophage-seeded collagen biotextiles revealed promising host tissue responses, such as reduced fibrous capsule thickness and minimal granulation tissue formation. Furthermore, the M2-seeded group displayed more abundant interstitial collagen deposition following degradation of the collagen threads. M2 macrophage supplementation improved structural and mechanical properties at the tissue and cellular level as indicated by increased modulus and stiffness. This study demonstrates improved biomechanical and histological outcomes following incorporation of M2 macrophages into genipin-cross-linked collagen biotextiles for tissue repair and offers future strategies focused on connective tissue regeneration. Impact statement: Macrophages exhibit significant plasticity with complex phenotypes ranging from proinflammatory (M1) to proregenerative (M2). They release cytokines and chemokines governing immunological stability, inflammation resolution, and tissue healing and regeneration. However, utilization of macrophages as therapeutic tools for tissue engineering remains limited. In this study, genipin-cross-linked collagen biotextiles were employed to deliver M0, M1, and M2 macrophages and evaluate tissue responses and postsurgical mechanical properties in vivo . M2-seeded collagen biotextiles showed reduced fibrous capsule and favorable healing response. These outcomes shed new light on designing tissue-engineered constructs that offer a novel cell-based therapeutic approach for applications requiring structural augmentation.